Reuters exclusively reports Ocugen plans to sell 100 million Indian vaccine doses in U.S.

Reuters exclusively reported that U.S.-based biopharmaceutical firm Ocugen Inc plans to sell 100 million doses of India’s state-backed COVID-19 vaccine in the United States. Ocugen is aiming to launch the Indian-developed vaccine in the United States in the second quarter of 2021, initially with imported shots before beginning production, the firm’s chief executive Shankar Musunuri told Reuters. Ocugen had held initial talks with the U.S. Food and Drug Administration and planned to seek emergency use authorization in April. 

Article Tags
Topics of Interest: Health
Type: Reuters Best
Sectors: Pharmaceuticals & Healthcare
Regions: AsiaNorth America
Countries: India
Win Types: Exclusivity
Story Types: Exclusive / Scoop
Media Types: Text
Customer Impact: Major Global Story
Sign up for email updates

Sign up for email updates